Could a smarter hormone schedule keep prostate cancer in check longer?
NCT ID NCT06734130
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 37 times
Summary
This study tests a new approach for men with stage IV prostate cancer that still responds to hormone therapy. Instead of continuous hormone treatment, doctors adjust the timing based on PSA levels and add chemotherapy. The goal is to see if this strategy can keep the cancer sensitive to hormones for at least 3 years. The study involves 25 participants and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Caner Center
Tampa, Florida, 33612, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.